A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter. LOS...
New Phase I research showcases NR supplementation significantly increased cerebral NAD levels, and decreased levels of inflammatory cytokines in Parkinson's disease (PD) patients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2021. The financial results will be reported in a press release...
Newly granted continuation patent provides additional intellectual property protection for ChromaDex's Niagen® (patented nicotinamide riboside) ingredient LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent,...
ChromaDex's research & development program reaches 100 published peer-reviewed studies on Niagen® and other ingredients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program's (CERP™) 100th published...
Researchers publish new clinical data on NR supplementation, marking the 18th clinical trial on ChromaDex's Niagen® ingredient LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented...
ChromaDex announces supply agreement with Designs for Health, offering new Niagen®-formulated products LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements...
Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today...
New clinical research in ataxia-telangiectasia (AT) patients finds nicotinamide riboside (NR) improved Ataxia scores and increased antibody levels LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press release...